Prevalence of purchase of antihypertensive and serum lipid-reducing drugs in Sweden - Individual data from national registers

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 1, 2008, Pages 37-42

  Silwer, Louise ^a,b,d   Lundborg, Cecilia Stålsby ^a,b,c   Petzold, Max ^a,c  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b Apoteket AB   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NONE   (Sweden)

Author keywords

Antihypertensive; Cardiovascular disease; Drug prevalence; Drug use; Elderly; Primary prevention; Serum lipid reducing; Sweden

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; NITRATE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REGISTER; SWEDEN; UNSPECIFIED SIDE EFFECT;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRATES; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; REGISTRIES; SWEDEN; VASODILATOR AGENTS;

EID: 38649098186     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1515     Document Type: Article

References (21)

1. Swedish drug sales statistics (Svensk läkemedelsstatistik). National Corporation of Swedish Pharmacies (Apoteket AB), Stockholm 2001 [In Swedish].
2. Silwer L, Stålsby Lundborg C. Patterns of drug use during a 15 year period: data from a Swedish county 1988-2002. Pharmacoepidemiol Drug Saf 2005; 14: 813-820.
3. Nilsson JL, Melander A. Increased introduction, advertising, and sales of preventive drugs during 1986-2002 in Sweden. J Ambul Care Manage. 2006; 29: 238-249.
4. Drug therapy hand book (Läkemedelsboken). National Corporation of Swedish Pharmacies. Apoteket AB, Stockholm 2005 [In Swedish].
5. Wahlberg G. Primary prevention for hypercholesterolaemia. High level of HDL-cholesterol and female sex are underrated protective factors (Primärprevention vid hyperkolesterolemi. Högt HDL-kolesterol och kvinnligt kön underskattade skyddsfaktorer). Läkartidningen 2006; 103: 131-134. [In Swedish].
6. Creagh D, Neilson S, Collins A, et al. Established cardiovascular disease and CVD risk factors in a primary care population of middle-aged Irish men and women. Ir Med J 2002; 95: 298-301.
7. Moderately elevated blood pressure. A systematic review. Report number 170. The Swedish council on Technology assessment in health care (SBU). http://www.sbu.se/www/index.asp
8. Welch E. Hypertension. Nurs Stand 2003; 18: 45-53.
9. How is Sweden getting on? (Hur mår Sverige?). The national board of health and welfare [In Swedish]. http:www.socialstyrelsen.se/Statistik/ statistikdatabas/index.htm
10. Drug sales statistics (Xplain). Internal database at National Corporation of Swedish Pharmacies (Apoteket AB).
11. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005; 60: 543-551.
12. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, Mustard CA. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332: 659-662.
13. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
14. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Womeńs Heart and Health Study. J Epidemiol Community Health 2003; 57: 134-140.
15. Bischoff B, Silber S, Richartz BM, et al. Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 2006; 95: 405-412.
16. International Classification of Diseases (ICD), WHO. http://www.who.int/ whosis/icd1O
17. Statistics Sweden (SCB) Population statistics. 2005; http://www.scb.se
18. Hemingway H, McCallum A, Shipley M, et al. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 2006; 295: 1404-1411.
19. Foody JM, Rathore SS, Galusha D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 2006; 54: 421-430.
20. Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy. Schweiz Rundsch Med Prax 2006; 95: 139-146.
21. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.